CHICAGO--(BUSINESS WIRE)--GTCR, a leading private equity firm, announced that it has completed the previously announced sale of its portfolio company Cord Blood Registry (“CBR” or the “Company”) to AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company that focuses on maternal health and hematology, for $700 million. Founded in 1992, CBR is the world’s largest newborn stem cell company, entrusted by parents with storing over 600,000 stem cell samples. CBR is dedicated to
| < Prev | Next > |
|---|
